Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases

被引:148
作者
Delgado, M [1 ]
Abad, C [1 ]
Martinez, C [1 ]
Juarranz, MG [1 ]
Arranz, A [1 ]
Gomariz, RP [1 ]
Leceta, J [1 ]
机构
[1] Univ Complutense Madrid, Fac Biol, Dept Biol Celular, E-28040 Madrid, Spain
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2002年 / 80卷 / 01期
关键词
vasoactive intestinal peptide; inflammation; autoimmunity; arthritis; endotoxic shock; neuroimmunology;
D O I
10.1007/s00109-001-0291-5
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Vasoactive intestinal peptide (VIP). a neuropeptide that is produced by lymphoid as well as neural cells. exerts a wide spectrum of immunological functions, controlling the homeostasis of the immune system through different receptors expressed in various immunocompetent cells. In the last decade. VIP has been clearly identified as a potent anti-inflammatory factor, which acts by regulating the production of both anti- and pro-inflammatory mediators. In this sense, VIP has been described to prevent death by septic shock, an acute inflammatory disease with a high mortality. In addition, VIP regulates the expression of co-stimulatory molecules, this being an action that may be related to modulating the shift toward Th1 and Th2 differentiation. We have recently reported that VIP prevents the deleterious effects of in experimental model of rheumatoid arthritis, by downregulating both inflammatory and autoimmune components of the disease. Therefore, VIP has been proposed as a promising, candidate alternative treatment for acute and chronic inflammatory and autoimmune diseases such as septic shock. arthritis, multiple sclerosis, Crohn disease, or autoimmune diabetes.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 102 条
[1]   The neuroendocrine immune basis of rheumatic diseases [J].
Bijlsma, JWJ ;
Cutolo, M ;
Masi, AT ;
Chikanza, IC .
IMMUNOLOGY TODAY, 1999, 20 (07) :298-301
[2]   Molecular tinkering of G protein-coupled receptors: an evolutionary success [J].
Bockaert, J ;
Pin, JP .
EMBO JOURNAL, 1999, 18 (07) :1723-1729
[3]   The physiologic basis for anticytokine clinical trials in the treatment of sepsis [J].
Cain, BS ;
Meldrum, DR ;
Harken, AH ;
McIntyre, RC .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (03) :337-350
[4]   INTERACTION OF VASOACTIVE-INTESTINAL-PEPTIDE (VIP) WITH HUMAN PERIPHERAL-BLOOD LYMPHOCYTES - SPECIFIC BINDING AND CYCLIC-AMP PRODUCTION [J].
CALVO, JR ;
GUERRERO, JM ;
MOLINERO, P ;
BLASCO, R ;
GOBERNA, R .
GENERAL PHARMACOLOGY, 1986, 17 (02) :185-189
[5]   CHARACTERISTICS OF RECEPTORS FOR VIP IN RAT PERITONEAL MACROPHAGE MEMBRANES [J].
CALVO, JR ;
GUERRERO, JM ;
LOPEZGONZALEZ, MA ;
OSUNA, C ;
SEGURA, JJ .
PEPTIDES, 1994, 15 (02) :309-315
[6]   Molecular cloning of a novel variant of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor that stimulates calcium influx by activation of L-type calcium channels [J].
Chatterjee, TK ;
Sharma, RV ;
Fisher, RA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :32226-32232
[7]   HUMAN INTESTINAL VIP RECEPTOR - CLONING AND FUNCTIONAL EXPRESSION OF 2 CDNA-ENCODING PROTEINS WITH DIFFERENT N-TERMINAL DOMAINS [J].
COUVINEAU, A ;
ROUYERFESSARD, C ;
DARMOUL, D ;
MAORET, JJ ;
CARRERO, I ;
OGIERDENIS, E ;
LABURTHE, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 200 (02) :769-776
[8]   RELEASE OF VASOACTIVE INTESTINAL POLYPEPTIDE IN MAST-CELLS BY HISTAMINE LIBERATORS [J].
CUTZ, E ;
CHAN, W ;
TRACK, NS ;
GOTH, A ;
SAID, SI .
NATURE, 1978, 275 (5681) :661-662
[9]   Regulation of VIP gene expression in general - Human lung cancer cells in particular [J].
Davidson, A ;
Moody, TW ;
Gozes, I .
JOURNAL OF MOLECULAR NEUROSCIENCE, 1996, 7 (02) :99-110
[10]   VIP modulation of immune cell functions [J].
DelaFuente, M ;
Delgado, M ;
Gomariz, RP .
ADVANCES IN NEUROIMMUNOLOGY, 1996, 6 (01) :75-91